Insider Buying: RxSight, Inc. (NASDAQ:RXST) Director Acquires 11,111 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) Director Jesse Anderson Corley bought 11,111 shares of the stock in a transaction on Tuesday, November 12th. The shares were bought at an average price of $45.37 per share, for a total transaction of $504,106.07. Following the completion of the transaction, the director now directly owns 468,571 shares of the company’s stock, valued at $21,259,066.27. This trade represents a 2.43 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

RxSight Trading Up 2.0 %

NASDAQ:RXST opened at $45.05 on Friday. The company’s 50-day moving average is $50.32 and its two-hundred day moving average is $53.27. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -54.28 and a beta of 1.19. RxSight, Inc. has a 12-month low of $27.07 and a 12-month high of $66.54.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on RXST shares. Stifel Nicolaus lowered their price target on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Wells Fargo & Company dropped their price target on RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Jefferies Financial Group began coverage on shares of RxSight in a research report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $66.00 target price on shares of RxSight in a report on Friday, September 13th. Finally, Oppenheimer reduced their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a report on Tuesday, August 6th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, RxSight presently has a consensus rating of “Buy” and a consensus target price of $61.63.

Institutional Trading of RxSight

Several hedge funds and other institutional investors have recently bought and sold shares of RXST. CWM LLC boosted its holdings in shares of RxSight by 727.5% during the second quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after purchasing an additional 371 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in RxSight by 854.1% during the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after buying an additional 521 shares during the period. Quarry LP boosted its stake in RxSight by 82.3% in the 3rd quarter. Quarry LP now owns 638 shares of the company’s stock worth $32,000 after buying an additional 288 shares during the last quarter. Point72 Hong Kong Ltd purchased a new stake in RxSight in the 3rd quarter valued at about $34,000. Finally, Quest Partners LLC acquired a new position in shares of RxSight during the 2nd quarter valued at about $41,000. 78.78% of the stock is owned by hedge funds and other institutional investors.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.